Whole genome sequencing in adults with clinical hallmarks of hypophosphatasia negative for ALPL variants.

Autor: Seefried L; Clinical Trial Unit, Orthopedic Department, University of Würzburg, Brettreichtstr. 11, 97074, Würzburg, Bavaria, Germany. l-seefried.klh@uni-wuerzburg.de., Petryk A; Alexion, AstraZeneca Rare Disease, Boston, MA, USA., Del Angel G; Alexion, AstraZeneca Rare Disease, Boston, MA, USA., Reder F; Centogene GmbH, Rostock, Germany., Bauer P; Centogene GmbH, Rostock, Germany.
Jazyk: angličtina
Zdroj: Molecular biology reports [Mol Biol Rep] 2024 Sep 14; Vol. 51 (1), pp. 984. Date of Electronic Publication: 2024 Sep 14.
DOI: 10.1007/s11033-024-09906-7
Abstrakt: Background: Hypophosphatasia (HPP) is a rare disease caused by deficient activity of tissue-nonspecific alkaline phosphatase (ALP), encoded by the ALPL gene. The primary objective was to explore novel ALPL variants by whole genome sequencing (WGS) in patients with HPP who previously tested negative by standard methods for ALPL variants. The secondary objective was to search for genes beyond ALPL that may reduce ALP activity or contribute to HPP symptoms.
Methods and Results: WGS was performed in 16 patients clinically diagnosed with HPP who had ALP activity below the normal range and tested negative for ALPL variants. Genetic variants in ALPL and genes possibly associated with low ALP activity or phenotypic overlap with HPP were assessed. All 16 patients had ALP activity below the normal range. WGS did not identify any novel disease-causing ALPL variants. Positive findings for other gene variants were identified in 4 patients: 1 patient presented with variants in COL1A1, NLRP12, and SCN9A, coding for collagen, type, I alpha-1 chain, nod-like receptor pyrin domain containing 12, and sodium voltage-gated channel alpha subunit 9, respectively; 1 presented with a heterozygous, likely pathogenic variant in P3H1 coding for prolyl 3 hydroxylase 1; 1 presented with a heterozygous pathogenic variant in SGCE, coding for sarcoglycan epsilon; and 1 presented with a heterozygous variant of uncertain significance in VDR, encoding vitamin D receptor.
Conclusion: Genomic analysis did not identify novel ALPL variants or a pattern of disease-causing variants in genes other than ALPL to explain the HPP phenotype in these patients.
Registration: Clinicaltrials.gov identifier: NCT04925804.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: